Board of Directors
Graham is the Co-Founder and the CEO of Kyruus. Prior to Kyruus, Graham was a Venture Executive at Highland Capital Partners where he co-founded Generation Health and served as the company's Chief Medical Officer through the acquisition of a majority of the shares by CVS Caremark. Graham completed his clinical training in internal medicine and cardiology at Beth Israel Deaconess Medical Center and Harvard Medical School, where he also served as Chief Medical Resident. He is the author of several peer review articles and has served as a consultant to a number of leading pharmaceutical and medical device companies. Graham completed his BA and MD degrees at Brown University, and received his MBA from Harvard Business School.
Bob is a Co-Founder and General Partner at Highland Capital Partners. Bob has more than twenty-five years of experience in venture capital and has served as a director of many public and private companies, including AVEO Pharmaceuticals (NASDAQ:AVEO), Conor Medsystems, (IPO/acquired), Generation Health, and Redbrick Health. Bob has also been a faculty member at the Harvard Business School since 2001 where he teaches a second-year course called Entrepreneurship and Venture Capital in Health care and a faculty member at the Kennedy School of Government where he teaches a course called Entrepreneurship in the Private, Public, and Social Sectors. He is a former director of the National Venture Capital Association and President of the New England Venture Capital Association. In addition, Bob has been recognized by the prestigious Forbes Midas List and AlwaysOn Venture Capital 100 as one of the top venture capitalists in the industry, and has earned the 2008 HBS Health care Alumni Achievement Award. Prior to his career in venture capital, Bob spent four years as the Executive Director of the John A. Hartford Foundation. He also was the Chief Executive of the Clark Foundation and the Burden Foundation. Bob is a former Assistant to the U.S. Secretary of Commerce and an Assistant to the head of the international division of the U.S. Treasury. Bob has an AB from Harvard University and received his MBA from Harvard Business School.
Ed Park has served as athenahealth's Executive Vice President and Chief Operating Officer since July 2010. He served as the Chief Technology Officer from March 2007 to July 2010 and served as Chief Software Architect from 1998 to March 2007. Mr. Park serves on the boards of Kyruus, Healthpoint Services Pvt. Ltd., and Castlight (observer). Prior to joining the Company, Mr. Park was a consultant for Viant, Inc. Mr. Park obtained a Bachelor of Arts magna cum laude from Harvard College in Computer Science.
Robert is Co-Founder of Lux Capital and focuses on ventures in healthcare. Robert graduated from the University of Virginia and has been a member of the Regional Selection Committee for UVA's Jefferson Scholars Foundation. Robert was also a member of Motorola's Research Visionary Board and an invited lecturer at the Memorial Sloan-Kettering Cancer Center, the National Cancer Institute, Yale University, Georgetown, and the University of Virginia. He has been published in Journal of Biomedical Materials Research (Applied Biomaterials) and Nature Biotechnology. Robert was Founding CEO and is currently on the Board of Directors at Harvard Medical School spinout Genocea Biosciences (vaccine discovery). In 2009, Robert was nominated as Biotech CEO of the Year at the World Vaccine Congress. In 2010, Robert was selected as one of the "100 of the Most Inspiring People" by PharmaVoice Magazine. Robert is Co-Founder of Lux Research (emerging technology research), Founding CEO of Kala Pharmaceuticals (mucosal drug delivery), and has served as an Advisor to the Bill & Melinda Gates Foundation.
Bryan is a Partner at Venrock, joining the firm as a Kauffman Fellow in 1997. He is based in Venrock's Palo Alto office and focuses on a broad range of health care investments. Bryan is currently Chairman of the Board of Directors of Achaogen, Castlight Health, and Ironwood Pharmaceuticals (NASDAQ: IRWD) and also serves on the Board of several other private companies, including Coderyte, Intarcia, Kyruus and Tandem Diagnostics. Past investments include athenahealth (NASDAQ: ATHN), Illumina (NASDAQ: ILMN), Sirna Therapeutics (acquired by Merck) and Xenoport (NASDAQ: XNPT). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has been the highest-ranking health care investor on Forbesâ Midas List since 2008. Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.
Julie is a Co-Founder of Kyruus and has over 10 years of experience in healthcare analytics and business intelligence software companies. She was previously the VP of Clinical Product Strategy at Generation Health (acquired by CVS Caremark), where she oversaw the development of the company's clinical programs and claims analysis platform. She also led the Product Management efforts at Knome, where she developed and launched a bioinformatics platform for conducting individualized genomic sequence analysis. Julie's passion for data-driven businesses began as a software engineer at Endeca Technologies, where she was a member of the team responsible for Information Access solutions in the health care industry. Julie has an undergraduate degree in computer science from MIT, an MS in biomedical sciences from the Harvard-MIT HST Program, and an MBA from the MIT Sloan School of Management.